Could a cocktail of three drugs tame a rare paralyzing disease?
NCT ID NCT02314208
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested three drugs—Xenbilox, Tahor, and resveratrol—in 12 adults with SPG5, a rare genetic condition causing progressive leg weakness. The goal was to lower levels of a toxic cholesterol byproduct called 27-hydroxycholesterol. Each drug was taken for 2 months, and blood levels were measured before and after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Xenbilox (chenodeoxycholic acid), Tahor (atorvastatin), and resveratrol
- What this could lead to
- If successful, this could point toward a treatment to slow or manage SPG5 by reducing toxic oxysterol buildup.
- What could go wrong
- This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drugs may not effectively lower oxysterols or improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPASTIC PARAPLEGIA TYPE 5 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pitié-Salpêtrière Hospital
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.